Biology subjects

Reyes Gaido, O. E.

Publications and source records attributed to Reyes Gaido, O. E..

7 recordsLinked to original sources

bioRxiv2025

Cell type specific CaMKII activation patterns revealed by CaMKAR, a bioactivity reporter deployable in living cells

An accurate and precise mechanism for measuring CaMKII activity in living cells is invaluable in the search for effective and targeted CaMKII-based therapeutics. Here, we employ our recently published CaMKII Activity Reporter (CaMKAR) biosensor in order to investigate the spatiotemporal dynamics of CaMKII activation in three different types of cells - cardiac myocytes, skeletal myocytes, and neurons. In doing so, we found a greater rate of CaMKII activation in skeletal muscle compared to cardiac muscle and also delineated CaMKARs ability to measure discrete CaMKII activation events in the presence of individual action potentials. By modifying the original CaMKAR sequence, we generated sensors that can be localized to subcellular compartments and thereby preferentially detect the activity of specific spatially-distributed CaMKII isoforms. Finally, we utilized the live-cell data to generate mathematical models of CaMKII activation kinetics, both as an integrated function across multiple calcium transients and as discrete on-off events following individual depolarizations. By furthering our understanding of CaMKII activity profiles across cell types and within subcellular compartments, we hope to support development of CaMKII inhibitors that are optimally precise and potent.

molecular biology↗

bioRxiv2023

HCN channels sense temperature and determine heart rate responses to heat

Heart rate increases with heat, [1-3] constituting a fundamental physiological relationship in vertebrates. Each normal heartbeat is initiated by an action potential generated in a sinoatrial nodal pacemaker cell. Pacemaker cells are enriched with hyperpolarization activated cyclic nucleotide-gated ion channels (HCN) that deliver cell membrane depolarizing inward current that triggers action potentials. HCN channel current increases due to cAMP binding, a mechanism coupling adrenergic tone to physiological fight or flight heart rate acceleration. However, the mechanism(s) for heart rate response to thermal energy is unknown. We used thermodynamical and homology computational modeling, site-directed mutagenesis and mouse models to identify a concise motif on the S4-S5 linker of the cardiac pacemaker HCN4 channels (M407/Y409) that determines HCN4 current (If) and cardiac pacemaker cell responses to heat. This motif is required for heat sensing in cardiac pacemaker cells and in isolated hearts. In contrast, the cyclic nucleotide binding domain is not required for heat induced HCN4 current increases. However, a loss of function M407/Y409 motif mutation prevented normal heat and cAMP responses, suggesting that heat sensing machinery is essential for operating the cAMP allosteric pathway and is central to HCN4 modulation. The M407/Y409 motif is conserved across all HCN family members suggesting that HCN channels participate broadly in coupling heat to changes in cell membrane excitability.

physiology↗

bioRxiv2023

Genome-wide CRISPR screen reveals genetic modifiers of Ca2+-mediated cell death

Ca2+ is a fundamental determinant of survival in living cells. Excessive intracellular Ca2+ causes cellular toxicity and death but the genetic pathways contributing to Ca2+ induced cell death are incompletely understood. Here, we performed genome-wide CRISPR knock-out screening in human cells challenged with the Ca2+ ionophore ionomycin and identified genes and pathways essential for cell death after Ca2+ overload. We discovered 115 protective gene knockouts, 82 of which are non-essential genes and 21 of which belong to the druggable genome. Notably, members of store operated Ca2+ entry (SOCE), very long-chain fatty acid synthesis, and SWItch/Sucrose Non-Fermentable (SWI/SNF) pathways provided marked protection against Ca2+ toxicity. These results reveal pathways previously unknown to mediate Ca2+-induced cell death and provide a resource for the development of pharmacotherapies against the sequelae of Ca2+ overload in disease.

cell biology↗

bioRxiv2022

Improving the sensitivity of in vivo CRISPR off-target detection with DISCOVER-Seq+

Discovery of off-target CRISPR-Cas genome editing activity in patient-derived cells and animal models is crucial for therapeutic applications, but currently exhibits low sensitivity. We demonstrate that inhibition of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) accumulates repair protein MRE11 at CRISPR-targeted sites, enabling high-sensitivity mapping of off-target sites to positions of MRE11 binding using chromatin immunoprecipitation sequencing (ChIP-seq). This technique, termed DISCOVER-Seq+, discovered up to 5-fold more CRISPR off-target sites in immortalized cell lines, primary human cells, and mice compared to previous methods. We demonstrated applicability to ex vivo knock-in of a cancer-directed transgenic T-cell receptor in primary human T cells and in vivo adenovirus knock-out of cardiovascular risk gene PCSK9 in mice. DISCOVER-Seq+ is the most sensitive method to-date for discovering off-target genome editing in vivo.

bioengineering↗

bioRxiv2022

Novel Biosensor Identifies Ruxolitinib as a Potent and Cardioprotective CaMKII Inhibitor

Ca2+/Calmodulin-dependent protein kinase II (CaMKII) hyperactivity causes heart injury and arrhythmias--two major sources of mortality worldwide. Despite proven benefits of CaMKII inhibition in numerous preclinical models of heart disease, translation of CaMKII antagonists into humans has been stymied by low potency, toxicity, and an enduring concern for adverse effects on cognition due to an established role of CaMKII in learning and memory. To address these challenges, we asked if any clinically approved drugs, developed for other purposes, were potent CaMKII inhibitors. For this, we engineered a novel fluorescent biosensor, CaMKAR (CaMKII Activity Reporter), which features superior sensitivity, kinetics, and tractability for high throughput screening. Using this tool, we carried a drug repurposing screen (4,475 compounds in clinical use) in human cells expressing autonomously active CaMKII. This yielded five previously unrecognized CaMKII inhibitors with clinically relevant potency: ruxolitinib, baricitinib, silmitasertib, crenolanib, and abemaciclib. Standout among these, ruxolitinib, an orally bioavailable and U.S Food and Drug Administration (FDA)-approved medication, inhibited CaMKII in cultured cardiomyocytes and in mice at concentrations equivalent to human doses. 10-minute treatment in mice was sufficient to prevent atrial fibrillation-- the most common clinical arrhythmia. At cardioprotective doses, ruxolitinib-treated mice behaved normally in established cognitive assays. Our results suggest that human CaMKII inhibition is feasible and safe, and support prompt clinical investigation of ruxolitinib for cardiac indications. One Sentence SummaryWe developed a CaMKII biosensor suitable for high throughput screening and identified ruxolitinib as a CaMKII inhibitor capable of rescuing cardiac arrhythmia.

molecular biology↗

bioRxiv2020

Mitochondrial CaMKII causes metabolic reprogramming, energetic insufficiency, and dilated cardiomyopathy

Despite the clear association between myocardial injury, heart failure and depressed myocardial energetics, little is known about upstream signals responsible for remodeling myocardial metabolism after pathological stress. We found increased mitochondrial calmodulin kinase II (CaMKII) activation and left ventricular dilation in mice one week after myocardial infarction (MI) surgery. In contrast, mice with genetic mitochondrial CaMKII inhibition were protected from left ventricular dilation and dysfunction after MI. Mice with myocardial and mitochondrial CaMKII over-expression (mtCaMKII) had severe dilated cardiomyopathy and decreased ATP that caused elevated cytoplasmic resting (diastolic) Ca2+ concentration and reduced mechanical performance. We mapped a metabolic pathway that allowed us to rescue disease phenotypes in mtCaMKII mice, providing new insights into physiological and pathological metabolic consequences of CaMKII signaling in mitochondria. Our findings suggest myocardial dilation, a disease phenotype lacking specific therapies, can be prevented by targeted replacement of mitochondrial creatine kinase, or mitochondrial-targeted CaMKII inhibition.

molecular biology↗

bioRxiv2020

Excessive O-GlcNAcylation causes heart failure and sudden death

BackgroundHeart failure is a leading cause of death worldwide and is associated with the rising prevalence of obesity, hypertension and diabetes. O-GlcNAcylation, a post-translational modification of intracellular proteins, serves as a potent transducer of cellular stress. Failing myocardium is marked by increased O-GlcNAcylation, but it is unknown if excessive O-GlcNAcylation contributes to cardiomyopathy and heart failure. The total levels of O-GlcNAcylation are determined by nutrient and metabolic flux, in addition to the net activity of two enzymes, O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). MethodsWe developed two new transgenic mouse models with myocardial overexpression of OGT and OGA to control O-GlcNAclyation independent of pathological stress. ResultsWe found that OGT transgenic hearts showed increased O-GlcNAcylation, and developed severe dilated cardiomyopathy, ventricular arrhythmias and premature death. In contrast, OGA transgenic hearts had O-GlcNAcylation and cardiac function similar to wild type littermate controls. However, OGA trangenic hearts were resistant to pathological stress induced by pressure overload and had attenuated myocardial O-GlcNAcylation levels, decreased pathological hypertrophy and improved systolic function. Interbreeding OGT with OGA transgenic mice rescued cardiomyopathy and premature death despite persistant elevation of myocardial OGT. Transcriptomic and functional studies revealed disrupted mitochondrial energetics with impairment of complex I activity in hearts from OGT transgenic mice. Complex I activity was rescued by OGA transgenic interbreeding, suggesting an important role for mitochondrial complex I in O-GlcNAc mediated cardiac pathology. ConclusionsOur data provide evidence that excessive O-GlcNAcylation causes cardiomyopathy, at least in part, due to defective energetics. Enhanced OGA activity is well tolerated and attenuation of O-GlcNAcylation is an effective therapy against pressure overload induced heart failure. Attenuation of excessive O-GlcNAcylation may represent a novel therapeutic approach for cardiomyopathy. Clinical PerspectiveO_ST_ABSWhat is new?C_ST_ABSO_LICardiomyopathy from diverse causes is marked by increased O-GlcNAcylation. Here we provide new genetic mouse models to control myocardial O-GlcNAcylation independent of pathological stress. C_LIO_LIGenetically increased myocardial O-GlcNAcylation causes progressive dilated cardiomyopathy and premature death, while genetic reduction of myocardial O-GlcNAcylation is protective against pathological hypertrophy caused by transaortic banding. C_LIO_LIExcessive myocardial O-GlcNAcylation decreases activity and expression of mitochondrial complex I. C_LI What are the clinical implications?O_LIIncreased myocardial O-GlcNAcylation has been shown to be associated with a diverse range of clinical heart failure including aortic stenosis, hypertension, ischemia and diabetes. C_LIO_LIUsing novel genetic mouse models we have provided new proof of concept data that excessive O-GlcNAcylation is sufficient to cause cardiomyopathy. C_LIO_LIWe have shown myocardial over-expression of O-GlcNAcase, an enzyme that reverses O-GlcNAcylation, is well tolerated at baseline, and improves myocardial responses to pathological stress. C_LIO_LIOur findings suggest reversing excessive myocardial O-GlcNAcylation could benefit diverse etiologies of heart failure. C_LI

molecular biology↗